Research programme: cannabidiol-based therapeutics - KannaLife Sciences

Drug Profile

Research programme: cannabidiol-based therapeutics - KannaLife Sciences

Alternative Names: Cannabinoid-based antioxidants - KannaLife Sciences; Cannabinoid-based neuroprotectants - KannaLife Sciences; KLS-13019

Latest Information Update: 07 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator KannaLife Sciences
  • Class Analgesics; Anti-inflammatories; Benzene derivatives; Cannabinoids; Neuroprotectants; Small molecules
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain injuries; Hepatic encephalopathy; Neuropathic pain

Most Recent Events

  • 05 Jul 2017 Preclinical trials in Neuropathic pain in USA (unspecified route) before July 2017
  • 29 Feb 2016 Preclinical trials in Brain injuries in USA (unspecified route)
  • 04 Aug 2014 KannaLife Sciences in-licenses technology for use of cannabinoids for the treatment of Chronic brain injuries from National Institutes of Health
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top